{"groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG000","title":"Anaplastic Thyroid Cancer (ATC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG001","title":"Biliary Tract Cancer (BTC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG002","title":"Gastrointestinal Stromal Tumor (GIST)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG003","title":"Low Grade (WHO G1/G2) Glioma (LGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG004","title":"High Grade (WHO G3/G4) Glioma (HGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG005","title":"Adenocarcinoma of the Small Intestine (ASI)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG006","title":"Hairy Cell Leukemia (HCL)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"FG007","title":"Multiple Myeloma (MM)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"42"},{"groupId":"FG007","numSubjects":"0"}],"type":"Study closed by sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"45"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"55"},{"groupId":"FG007","numSubjects":"10"}],"comment":"All enrolled participants were included in the Intent-to-treat (ITT), All-treated subjects (ATS) and ITT/Evaluable populations","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"24"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"24"},{"groupId":"FG007","numSubjects":"10"}],"type":"Primary Analysis Cohort"},{"achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"25"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"31"},{"groupId":"FG007","numSubjects":"0"}],"type":"Expansion Cohort"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"28"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"17"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"47"},{"groupId":"FG007","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Subjects were enrolled into cohorts based on the type of histology. For each histology, up to 25 patients were planned to be enrolled. A cohort could be closed or stopped early (prior to capping at 25 patients) for futility or efficacy. An uncapped expansion cohort was planned when a particular cohort was stopped early for efficacy.","recruitmentDetails":"The study was conducted in 41 centers in 14 countries worldwide."}